Biotech firm SanegeneBio has secured $80 million in an extended Series A funding round led by Tencent and local healthcare-focused investment firm YuanBio Venture Capital.
Register now to enjoy 3 free articles per month,
or log in to continue reading.
Stay informed with complimentary articles each month
Gain access to our exclusive newsletters delivered directly to your inbox
Be the first to know about all our summits!
Already a Subscriber? Log in
